Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01
The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East